Compare SCLX & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCLX | ELOX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | 34 | 7 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 43.8M |
| IPO Year | N/A | N/A |
| Metric | SCLX | ELOX |
|---|---|---|
| Price | $9.43 | $11.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 118.9K | 44.1K |
| Earning Date | 04-10-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $122.52 | N/A |
| Revenue Next Year | $186.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.20 | $10.00 |
| 52 Week High | $34.27 | $15.00 |
| Indicator | SCLX | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 61.25 | 41.57 |
| Support Level | $7.73 | N/A |
| Resistance Level | $9.44 | $15.00 |
| Average True Range (ATR) | 0.97 | 2.29 |
| MACD | 0.24 | -0.11 |
| Stochastic Oscillator | 75.84 | 45.20 |
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.